Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1993 1
1994 1
1995 3
1996 1
1997 5
1998 11
1999 5
2000 11
2001 13
2002 21
2003 15
2004 17
2005 25
2006 25
2007 29
2008 31
2009 24
2010 34
2011 37
2012 40
2013 37
2014 39
2015 35
2016 27
2017 37
2018 27
2019 36
2020 41
2021 33
2022 38
2023 29
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

662 results

Results by year

Filters applied: . Clear all
Page 1
Antibody-drug conjugates: in search of partners of choice.
Fuentes-Antrás J, Genta S, Vijenthira A, Siu LL. Fuentes-Antrás J, et al. Among authors: siu ll. Trends Cancer. 2023 Apr;9(4):339-354. doi: 10.1016/j.trecan.2023.01.003. Epub 2023 Feb 4. Trends Cancer. 2023. PMID: 36746689 Free article. Review.
Molecular profiling for precision cancer therapies.
Malone ER, Oliva M, Sabatini PJB, Stockley TL, Siu LL. Malone ER, et al. Among authors: siu ll. Genome Med. 2020 Jan 14;12(1):8. doi: 10.1186/s13073-019-0703-1. Genome Med. 2020. PMID: 31937368 Free PMC article. Review.
Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022.
Araujo D, Greystoke A, Bates S, Bayle A, Calvo E, Castelo-Branco L, de Bono J, Drilon A, Garralda E, Ivy P, Kholmanskikh O, Melero I, Pentheroudakis G, Petrie J, Plummer R, Ponce S, Postel-Vinay S, Siu L, Spreafico A, Stathis A, Steeghs N, Yap C, Yap TA, Ratain M, Seymour L. Araujo D, et al. Among authors: siu l. Ann Oncol. 2023 Jan;34(1):48-60. doi: 10.1016/j.annonc.2022.09.158. Epub 2022 Sep 29. Ann Oncol. 2023. PMID: 36182023 Free article. Review.
Dose escalation methods in phase I cancer clinical trials.
Le Tourneau C, Lee JJ, Siu LL. Le Tourneau C, et al. Among authors: siu ll. J Natl Cancer Inst. 2009 May 20;101(10):708-20. doi: 10.1093/jnci/djp079. Epub 2009 May 12. J Natl Cancer Inst. 2009. PMID: 19436029 Free PMC article. Review.
Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial.
Chan ATC, Lee VHF, Hong RL, Ahn MJ, Chong WQ, Kim SB, Ho GF, Caguioa PB, Ngamphaiboon N, Ho C, Aziz MASA, Ng QS, Yen CJ, Soparattanapaisarn N, Ngan RK, Kho SK, Tiambeng MLA, Yun T, Sriuranpong V, Algazi AP, Cheng A, Massarelli E, Swaby RF, Saraf S, Yuan J, Siu LL. Chan ATC, et al. Among authors: siu ll. Ann Oncol. 2023 Mar;34(3):251-261. doi: 10.1016/j.annonc.2022.12.007. Epub 2022 Dec 16. Ann Oncol. 2023. PMID: 36535566 Free article. Clinical Trial.
Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab.
Bratman SV, Yang SYC, Iafolla MAJ, Liu Z, Hansen AR, Bedard PL, Lheureux S, Spreafico A, Razak AA, Shchegrova S, Louie M, Billings P, Zimmermann B, Sethi H, Aleshin A, Torti D, Marsh K, Eagles J, Cirlan I, Hanna Y, Clouthier DL, Lien SC, Ohashi PS, Xu W, Siu LL, Pugh TJ. Bratman SV, et al. Among authors: siu ll. Nat Cancer. 2020 Sep;1(9):873-881. doi: 10.1038/s43018-020-0096-5. Epub 2020 Aug 3. Nat Cancer. 2020. PMID: 35121950
662 results